Diphtheria, tetanus, acellular pertussis and polio (inactivated) vaccine

Diphtheria, tetanus, acellular pertussis and polio (inactivated) vaccine
REPEVAX (Tdap-IPV) vaccine in UK
Combination of
DTaP vaccineVaccine
Inactivated poliovirus vaccineVaccine
Names
Trade namesKinrix, Quadracel, Boostrix-IPV, Infanrix-IPV, others
Other namesdiphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • AU: A
    Routes of
    use    		Intramuscular injection
    External links
    AHFS/Drugs.comKinrix Quadracel
    Legal
    Legal status
    • In general: ℞ (Prescription only)
    Identifiers
    CAS Number
    • 1688606-07-6
    ATC code

    Diphtheria, tetanus, acellular pertussis and polio (inactivated) vaccine also known as a 4-in-1 vaccine, is a combination vaccine that protects against diphtheria, tetanus, pertussis and polio.[1] Types include Tdap/IPV, DTaP/IPV and dTaP/IPV.[2][3]

    The lower dose diphtheria types are used as a booster for children before starting school around the age of 3 years, when the MMR vaccine is also given.[1] In unimmunised older children and adults, it can be used as a course for primary immunisation.[1] Given towards the end of pregnancy, it can protect the new born baby from neonatal tetanus and pertussis.[4][5] The higher diphtheria dose (D) types can be used for primary immunisations in babies as a course of initially 3 doses 4 weeks apart, followed by a booster 3 years later.[4] In several countries, it is given in combination with vaccines against H. influenzae type B and hepatitis B.[2] Subsequent boosters can be given with the low dose type after 10 years.[4]

    Brands

    Branded formulations marketed in the USA are Kinrix from GlaxoSmithKline[6] and Quadracel from Sanofi Pasteur.[7] Repevax (Tdap/IPV) is available in the UK.[8][9] Within Japan, the formulation is called 四種混合（shishukongou - "mixture of 4"). Astellas markets it under the クアトロバック ('Quattro-back') formulation, while another is available from Mitsubishi Tanabe Pharma named テトラビック ('Tetrabic')[10][11] A previous product by Takeda Pharmaceutical Company has been withdrawn by the company.[12]

    • Boostrix-IPV
      Boostrix-IPV
    • Quattro-back
      Quattro-back

    References

    1. 1 2 3 "The 4-in-1 (DTaP/IPV or dTaP/IPV) vaccine: Overview". www.nhsinform.scot. Archived from the original on 3 July 2021. Retrieved 4 January 2022.
    2. 1 2 Domachowske, Joseph (2021). "29. Tetanus". In Domachowske, Joseph; Suryadevara, Manika (eds.). Vaccines: A Clinical Overview and Practical Guide. Switzerland: Springer. p. 347. ISBN 978-3-030-58416-0. Archived from the original on 2022-01-11. Retrieved 2022-01-08.
    3. ↑ Syed YY (October 2019). "DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination". Paediatric Drugs. 21 (5): 397–408. doi:10.1007/s40272-019-00353-7. PMC 6794236. PMID 31444785.
    4. 1 2 3 "14. Vaccines". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 1357–1377. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)
    5. ↑ Kollaritsch, Herwig; Heininger, Ulrich (2021). "18. Pertussis vaccines". In Vesikari, Timo; Damme, Pierre Van (eds.). Pediatric Vaccines and Vaccinations: A European Textbook (Second ed.). Switzerland: Springer. pp. 185–194. ISBN 978-3-030-77172-0. Archived from the original on 2022-01-11. Retrieved 2022-01-08.
    6. ↑ "Kinrix". US Food and Drug Administration. Archived from the original on 11 January 2022. Retrieved 15 July 2018.
    7. ↑ "Quadracel". US Food and Drug Administration. Archived from the original on 8 September 2018. Retrieved 15 July 2018.
    8. ↑ "Repevax, suspension for injection, in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Archived from the original on 17 April 2021. Retrieved 31 December 2020.
    9. ↑ "14. Vaccines". British National Formulary (BNF) (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1381. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
    10. ↑ "医療用医薬品 : テトラビック (テトラビック皮下注シリンジ)". www.kegg.jp. Archived from the original on 2021-09-14. Retrieved 2021-02-27.
    11. ↑ "医療用医薬品 : クアトロバック (クアトロバック皮下注シリンジ)". www.kegg.jp. Archived from the original on 2021-09-04. Retrieved 2021-02-27.
    12. ↑ "【武田薬品】４種混合ワクチンの開発中止‐ノロウイルスなどに資源投入｜薬事日報ウェブサイト". Archived from the original on 2021-01-21. Retrieved 2021-02-27.


    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.